TABLE 1

Demographic and clinical characteristics of patients included in the test cohort

Patient or test characteristicValue for:
Patient or testHyDRAbPASeq
Patient (n = 113)
 Age, yr, median (IQR)40 (33–49)
 Men, n (%)a103 (91)
 Plasma HIV RNA baseline in log10 copies/ml, median (IQR)4.2 (3.7–4.8)
 Missing plasma HIV RNA measure at baseline, n (%)27 (24)
 Subtype, n (%)
  B107 (95)
  C5
  A1
Test (n = 144)
 DRM reported by clinical genotyping (Sanger sequencing), n (% of tests)
  Any (>1)40 (28)
  PI2 (2)
  NRTI18 (17)
  NNRTI28 (27)
  INSTI1 (3)
 DRM detected by NGS, n (% of tests)
  Any (>1)60 (42)63 (44)
  PI11 (11)11 (10)
  NRTI27 (26)24 (23)
  NNRTI36 (34)39 (37)
  INSTI5 (13)4 (10)
  • a Percentages were calculated based on 113 unique patients in test cohort; 29 patients had both Pr-RT and INT tests, and 2 patients had a repeat Pr-RT test during the sample period.

  • b HyDRA-detected DRMs were used as the NGS-detected DRMs for subsequent analyses in the patient follow-up cohort that compared Sanger to NGS resistance profiles.